{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:21:17Z","timestamp":1791328877861,"version":"4.3.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,4,28]],"date-time":"2015-04-28T00:00:00Z","timestamp":1430179200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["107222"],"award-info":[{"award-number":["107222"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["632908"],"award-info":[{"award-number":["632908"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s10549-015-3397-0","type":"journal-article","created":{"date-parts":[[2015,4,27]],"date-time":"2015-04-27T05:21:53Z","timestamp":1430112113000},"page":"309-318","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Progesterone receptor A predominance is a discriminator of benefit from endocrine therapy in the ATAC trial"],"prefix":"10.1007","volume":"151","author":[{"given":"Patricia A.","family":"Mote","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Gompel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Howe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi N.","family":"Hilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Sestak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Cuzick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitch","family":"Dowsett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Hugol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Forgez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Byth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Dinny","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine L.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,28]]},"reference":[{"issue":"10\u201313","key":"3397_CR1","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0039-128X(03)00138-7","volume":"68","author":"RJ Santen","year":"2003","unstructured":"Santen RJ (2003) Risk of breast cancer with progestins: critical assessment of current data. Steroids 68(10\u201313):953\u2013964.\u00a0doi: 10.1016\/S0039-128X(03)00138-7","journal-title":"Steroids"},{"issue":"5","key":"3397_CR2","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0960-0760(00)00113-8","volume":"74","author":"I Persson","year":"2000","unstructured":"Persson I (2000) Estrogens in the causation of breast, endometrial and ovarian cancers\u2014evidence and hypotheses from epidemiological findings. J Steroid Biochem Mol Biol 74(5):357\u2013364","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"6","key":"3397_CR3","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrc3518","volume":"13","author":"C Brisken","year":"2013","unstructured":"Brisken C (2013) Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. Nat Rev Cancer 13(6):385\u2013396. doi: 10.1038\/nrc3518","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"3397_CR4","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1056\/NEJMoa0807684","volume":"360","author":"RT Chlebowski","year":"2009","unstructured":"Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, Aragaki AK, Ockene JK, Lane DS, Sarto GE, Rajkovic A, Schenken R, Hendrix SL, Ravdin PM, Rohan TE, Yasmeen S, Anderson G (2009) Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 360(6):573\u2013587. doi: 10.1056\/NEJMoa0807684","journal-title":"N Engl J Med"},{"issue":"8","key":"3397_CR5","first-page":"2963","volume":"84","author":"PA Mote","year":"1999","unstructured":"Mote PA, Balleine RL, McGowan EM, Clarke CL (1999) Colocalization of progesterone receptors A and B by dual immunofluorescent histochemistry in human endometrium during the menstrual cycle. J Clin Endocrinol Metab 84(8):2963\u20132971","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"3397_CR6","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1023\/A:1014820500738","volume":"72","author":"PA Mote","year":"2002","unstructured":"Mote PA, Bartow S, Tran N, Clarke CL (2002) Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis. Breast Cancer Res Treat 72(2):163\u2013172","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"3397_CR7","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/carcin\/24.3.403","volume":"24","author":"YC Chou","year":"2003","unstructured":"Chou YC, Uehara N, Lowry JR, Shyamala G (2003) Mammary epithelial cells of PR-A transgenic mice exhibit distinct alterations in gene expression and growth potential associated with transformation. Carcinogenesis 24(3):403\u2013409","journal-title":"Carcinogenesis"},{"issue":"4","key":"3397_CR8","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/molehr\/gap013","volume":"15","author":"MC Fleisch","year":"2009","unstructured":"Fleisch MC, Chou YC, Cardiff RD, Asaithambi A, Shyamala G (2009) Overexpression of progesterone receptor A isoform in mice leads to endometrial hyperproliferation, hyperplasia and atypia. Mol Hum Reprod 15(4):241\u2013249. doi: 10.1093\/molehr\/gap013","journal-title":"Mol Hum Reprod"},{"issue":"3","key":"3397_CR9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1023\/B:BREA.0000014041.58977.80","volume":"83","author":"EM McGowan","year":"2004","unstructured":"McGowan EM, Saad S, Bendall LJ, Bradstock KF, Clarke CL (2004) Effect of progesterone receptor A predominance on breast cancer cell migration into bone marrow fibroblasts. Breast Cancer Res Treat 83(3):211\u2013220","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"3397_CR10","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1158\/1078-0432.CCR-03-0141","volume":"10","author":"TA Hopp","year":"2004","unstructured":"Hopp TA, Weiss HL, Hilsenbeck SG, Cui Y, Allred DC, Horwitz KB, Fuqua SA (2004) Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res 10(8):2751\u20132760","journal-title":"Clin Cancer Res"},{"issue":"9472","key":"3397_CR11","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Early Breast Cancer Trialists' Collaborative Group","year":"2005","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687\u20131717","journal-title":"Lancet"},{"issue":"10","key":"3397_CR12","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1200\/JCO.1996.14.10.2738","volume":"14","author":"T Saphner","year":"1996","unstructured":"Saphner T, Tormey DC, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14(10):2738\u20132746","journal-title":"J Clin Oncol"},{"issue":"7","key":"3397_CR13","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1200\/JCO.2007.12.9437","volume":"26","author":"M Dowsett","year":"2008","unstructured":"Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E, Bishop H, Ellis I, Larsimont D, Sasano H, Carder P, Cussac AL, Knox F, Speirs V, Forbes J, Buzdar A (2008) Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 26(7):1059\u20131065. doi: 10.1200\/JCO.2007.12.9437","journal-title":"J Clin Oncol"},{"issue":"12","key":"3397_CR14","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","volume":"11","author":"J Cuzick","year":"2010","unstructured":"Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF, ATAC\/LATTE investigators (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11(12):1135\u20131141. doi: 10.1016\/S1470-2045(10)70257-6","journal-title":"Lancet Oncol"},{"issue":"8","key":"3397_CR15","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1185\/030079906X120940","volume":"22","author":"A Buzdar","year":"2006","unstructured":"Buzdar A, Chlebowski R, Cuzick J, Duffy S, Forbes J, Jonat W, Ravdin P (2006) Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer. Curr Med Res Opin 22(8):1575\u20131585. doi: 10.1185\/030079906X120940","journal-title":"Curr Med Res Opin"},{"issue":"Suppl 1","key":"3397_CR16","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1007\/s10549-004-1578-3","volume":"87","author":"M Dowsett","year":"2004","unstructured":"Dowsett M (2004) Biomarker investigations from the ATAC trial: the role of TA01. Breast Cancer Res Treat 87(Suppl 1):S11\u2013S18. doi: 10.1007\/s10549-004-1578-3","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"3397_CR17","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1210\/endo-121-3-1123","volume":"121","author":"CL Clarke","year":"1987","unstructured":"Clarke CL, Zaino RJ, Feil PD, Miller JV, Steck ME, Ohlsson-Wilhelm BM, Satyaswaroop PG (1987) Monoclonal antibodies to human progesterone receptor: characterization by biochemical and immunohistochemical techniques. Endocrinology 121(3):1123\u20131132. doi: 10.1210\/endo-121-3-1123","journal-title":"Endocrinology"},{"issue":"8","key":"3397_CR18","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1136\/jcp.54.8.624","volume":"54","author":"PA Mote","year":"2001","unstructured":"Mote PA, Johnston JF, Manninen T, Tuohimaa P, Clarke CL (2001) Detection of progesterone receptor forms A and B by immunohistochemical analysis. J Clin Pathol 54(8):624\u2013630","journal-title":"J Clin Pathol"},{"key":"3397_CR19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1746-1596-8-22","volume":"8","author":"M Khushi","year":"2013","unstructured":"Khushi M, Edwards G, de Marcos DA, Carpenter JE, Graham JD, Clarke CL (2013) Open source tools for management and archiving of digital microscopy data to allow integration with patient pathology and treatment information. Diagn Pathol 8:22. doi: 10.1186\/1746-1596-8-22","journal-title":"Diagn Pathol"},{"issue":"21","key":"3397_CR20","first-page":"5063","volume":"55","author":"JD Graham","year":"1995","unstructured":"Graham JD, Yeates C, Balleine RL, Harvey SS, Milliken JS, Bilous AM, Clarke CL (1995) Characterization of progesterone receptor A and B expression in human breast cancer. Cancer Res 55(21):5063\u20135068","journal-title":"Cancer Res"},{"issue":"18","key":"3397_CR21","doi-asserted-by":"crossref","first-page":"8651","DOI":"10.18632\/oncotarget.2354","volume":"5","author":"HN Hilton","year":"2014","unstructured":"Hilton HN, Doan TB, Graham JD, Oakes SR, Silvestri A, Santucci N, Kantimm S, Huschtscha LI, Ormandy CJ, Funder JW, Simpson ER, Kuczek ES, Leedman PJ, Tilley WD, Fuller PJ, Muscat GE, Clarke CL (2014) Acquired convergence of hormone signaling in breast cancer: ER and PR transition from functionally distinct in normal breast to predictors of metastatic disease. Oncotarget 5(18):8651\u20138664","journal-title":"Oncotarget"},{"issue":"2","key":"3397_CR22","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1023\/A:1023925906199","volume":"79","author":"E Isaksson","year":"2003","unstructured":"Isaksson E, Wang H, Sahlin L, von Schoultz B, Cline JM, von Schoultz E (2003) Effects of long-term HRT and tamoxifen on the expression of progesterone receptors A and B in breast tissue from surgically postmenopausal cynomolgus macaques. Breast Cancer Res Treat 79(2):233\u2013239","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"3397_CR23","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1471-0528.1978.tb10468.x","volume":"85","author":"T Lind","year":"1978","unstructured":"Lind T, Cameron EH, Hunter WM (1978) Serum prolactin, gonadotrophin and oestrogen levels in women receiving hormone replacement therapy. Br J Obstet Gynaecol 85(2):138\u2013141","journal-title":"Br J Obstet Gynaecol"},{"issue":"51","key":"3397_CR24","doi-asserted-by":"crossref","first-page":"30693","DOI":"10.1074\/jbc.270.51.30693","volume":"270","author":"JD Graham","year":"1995","unstructured":"Graham JD, Roman SD, McGowan E, Sutherland RL, Clarke CL (1995) Preferential stimulation of human progesterone receptor B expression by estrogen in T-47D human breast cancer cells. J Biol Chem 270(51):30693\u201330700","journal-title":"J Biol Chem"},{"issue":"4\u20136","key":"3397_CR25","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0960-0760(97)00119-2","volume":"63","author":"RK Mangal","year":"1997","unstructured":"Mangal RK, Wiehle RD, Poindexter AN 3rd, Weigel NL (1997) Differential expression of uterine progesterone receptor forms A and B during the menstrual cycle. J Steroid Biochem Mol Biol 63(4\u20136):195\u2013202","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"11","key":"3397_CR26","first-page":"1175","volume":"12","author":"JR Daling","year":"2003","unstructured":"Daling JR, Malone KE, Doody DR, Voigt LF, Bernstein L, Marchbanks PA, Coates RJ, Norman SA, Weiss LK, Ursin G, Burkman RT, Deapen D, Folger SG, McDonald JA, Simon MS, Strom BL, Spirtas R (2003) Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50\u201364 years. Cancer Epidemiol Biomark Prev 12(11):1175\u20131181","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"3","key":"3397_CR27","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1053\/ctrv.2000.0207","volume":"27","author":"NJ Bundred","year":"2001","unstructured":"Bundred NJ (2001) Prognostic and predictive factors in breast cancer. Cancer Treat Rev 27(3):137\u2013142. doi: 10.1053\/ctrv.2000.0207","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"3397_CR28","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/0277-5379(91)90418-D","volume":"27","author":"I Mittra","year":"1991","unstructured":"Mittra I, MacRae KD (1991) A meta-analysis of reported correlations between prognostic factors in breast cancer: does axillary lymph node metastasis represent biology or chronology? Eur J Cancer 27(12):1574\u20131583","journal-title":"Eur J Cancer"},{"issue":"12","key":"3397_CR29","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/modpathol.3800229","volume":"17","author":"SK Mohsin","year":"2004","unstructured":"Mohsin SK, Weiss H, Havighurst T, Clark GM, Berardo M, le Roanh D, To TV, Qian Z, Love RR, Allred DC (2004) Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol 17(12):1545\u20131554. doi: 10.1038\/modpathol.3800229","journal-title":"Mod Pathol"},{"issue":"9","key":"3397_CR30","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1200\/JCO.2010.31.6455","volume":"29","author":"M Colleoni","year":"2011","unstructured":"Colleoni M, Giobbie-Hurder A, Regan MM, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Lang I, Smith I, Chirgwin J, Pienkowski T, Wardley A, Price KN, Gelber RD, Coates AS, Goldhirsch A (2011) Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol 29(9):1117\u20131124. doi: 10.1200\/jco.2010.31.6455","journal-title":"J Clin Oncol"},{"issue":"17","key":"3397_CR31","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1093\/jnci\/dji249","volume":"97","author":"G Arpino","year":"2005","unstructured":"Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM (2005) Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 97(17):1254\u20131261","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"3397_CR32","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.breast.2005.08.024","volume":"14","author":"CK Osborne","year":"2005","unstructured":"Osborne CK, Schiff R, Arpino G, Lee AS, Hilsenbeck VG (2005) Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. Breast 14(6):458\u2013465","journal-title":"Breast"},{"issue":"17","key":"3397_CR33","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1158\/0008-5472.CAN-05-0746","volume":"65","author":"K Jirstrom","year":"2005","unstructured":"Jirstrom K, Stendahl M, Ryden L, Kronblad A, Bendahl PO, Stal O, Landberg G (2005) Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Res 65(17):8009\u20138016. doi: 10.1158\/0008-5472.CAN-05-0746","journal-title":"Cancer Res"},{"issue":"5","key":"3397_CR34","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1002\/j.1460-2075.1990.tb08280.x","volume":"9","author":"P Kastner","year":"1990","unstructured":"Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P (1990) Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 9(5):1603\u20131614","journal-title":"EMBO J"},{"issue":"11","key":"3397_CR35","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1210\/me.2005-0126","volume":"19","author":"JD Graham","year":"2005","unstructured":"Graham JD, Yager ML, Hill HD, Byth K, O\u2019Neill GM, Clarke CL (2005) Altered progesterone receptor isoform expression remodels progestin responsiveness of breast cancer cells. Mol Endocrinol 19(11):2713\u20132735","journal-title":"Mol Endocrinol"},{"issue":"31","key":"3397_CR36","doi-asserted-by":"crossref","first-page":"27793","DOI":"10.1074\/jbc.M202584200","volume":"277","author":"BM Jacobsen","year":"2002","unstructured":"Jacobsen BM, Richer JK, Schittone SA, Horwitz KB (2002) New human breast cancer cells to study progesterone receptor isoform ratio effects and ligand-independent gene regulation. J Biol Chem 277(31):27793\u201327800. doi: 10.1074\/jbc.M202584200","journal-title":"J Biol Chem"},{"key":"3397_CR37","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1741-7015-12-32","volume":"12","author":"CR Hagan","year":"2014","unstructured":"Hagan CR, Lange CA (2014) Molecular determinants of context-dependent progesterone receptor action in breast cancer. BMC Med 12:32. doi: 10.1186\/1741-7015-12-32","journal-title":"BMC Med"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-015-3397-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-015-3397-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-015-3397-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T00:29:44Z","timestamp":1566606584000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-015-3397-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,28]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["3397"],"URL":"https:\/\/doi.org\/10.1007\/s10549-015-3397-0","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,28]]}}}